QUARTERLY REPORT

Q2 2022 — Quarterly report

Q2 2022PDF · 29 pages176 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2022
or
 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM 	TO
Commission File Number: 1-10864
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
41-1321939
(I.R.S. Employer
Identification No.)
UnitedHealth Group Center
9900 Bren Road East
Minnetonka, Minnesota
(Address of principal executive offices)
55343
(Zip Code)
(952) 936-1300
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $.01 par value 	UNH 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. 	Yes  	No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to
Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files). 	Yes  	No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer 	 	Accelerated filer  	Non-accelerated filer 	
Smaller reporting company  	Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 	Yes  	No 
As of July 29, 2022, there were 935,382,710 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

-- 1 of 29 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. 	Financial Statements (unaudited)............................................................................................................... 	1
Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 .............................................. 	1
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2022 and 2021 ............. 	2
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June 30, 2022 and
2021.............................................................................................................................................. 	3
Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30, 2022 and 2021.... 	4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 ......................... 	6
Notes to the Condensed Consolidated Financial Statements............................................................................... 	7
1. 	Basis of Presentation ....................................................................................................................... 	7
2. 	Investments .................................................................................................................................. 	8
3. 	Fair Value .................................................................................................................................... 	10
4. 	Medical Costs Payable ..................................................................................................................... 	11
5. 	Short-Term Borrowings and Long-Term Debt......................................................................................... 	12
6. 	Dividends .................................................................................................................................... 	12
7. 	Commitments and Contingencies ........................................................................................................ 	12
8. 	Business Combinations .................................................................................................................... 	13
9. 	Segment Financial Information........................................................................................................... 	14
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations ......................................... 	16
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 	24
Item 4. 	Controls and Procedures ......................................................................................................................... 	24
Part II. Other Information
Item 1. 	Legal Proceedings ................................................................................................................................ 	25
Item 1A. 	Risk Factors........................................................................................................................................ 	25
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds ............................................................................. 	25
Item 6. 	Exhibits ............................................................................................................................................. 	26
Signatures ......................................................................................................................................................... 	27

-- 2 of 29 --

PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)
June 30,
2022
December 31,
2021
Assets
Current assets:
Cash and cash equivalents..................................................................................................... 	$ 	24,612 	$ 	21,375
Short-term investments ........................................................................................................ 	3,352 	2,532
Accounts receivable, net....................................................................................................... 	18,718 	14,216
Other current receivables, net................................................................................................. 	12,439 	13,866
Assets under management..................................................................................................... 	4,017 	4,449
Prepaid expenses and other current assets .................................................................................. 	5,218 	5,320
Total current assets ................................................................................................................... 	68,356 	61,758
Long-term investments............................................................................................................... 	42,427 	43,114
Property, equipment and capitalized software, net .............................................................................. 	9,421 	8,969
Goodwill ............................................................................................................................... 	84,159 	75,795
Other intangible assets, net.......................................................................................................... 	11,285 	10,044
Other assets ............................................................................................................................ 	14,524 	12,526
Total assets............................................................................................................................ 	$ 	230,172 	$ 	212,206
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable.......................................................................................................... 	$ 	28,978 	$ 	24,483
Accounts payable and accrued liabilities ................................................................................... 	25,145 	24,643
Short-term borrowings and current maturities of long-term debt ....................................................... 	5,592 	3,620
Unearned revenues ............................................................................................................. 	2,212 	2,571
Other current liabilities ........................................................................................................ 	26,771 	22,975
Total current liabilities............................................................................................................... 	88,698 	78,292
Long-term debt, less current maturities ........................................................................................... 	45,799 	42,383
Deferred income taxes ............................................................................................................... 	2,581 	3,265
Other liabilities........................................................................................................................ 	11,967 	11,787
Total liabilities ........................................................................................................................ 	149,045 	135,727
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests .............................................................................................. 	4,922 	1,434
Equity:
Preferred stock, $0.001 par value—10 shares authorized; no shares issued or outstanding ........................ 	— 	—
Common stock, $0.01 par value—3,000 shares authorized; 935 and 941 issued and outstanding ................ 	10 	10
Retained earnings ............................................................................................................... 	80,540 	77,134
Accumulated other comprehensive loss..................................................................................... 	(7,730) 	(5,384)
Nonredeemable noncontrolling interests .................................................................................... 	3,385 	3,285
Total equity ............................................................................................................................ 	76,205 	75,045
Total liabilities, redeemable noncontrolling interests and equity ........................................................ 	$ 	230,172 	$ 	212,206
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
(in millions, except per share data) 	2022 	2021 	2022 	2021
Three Months Ended
June 30,
Six Months Ended
June 30,
Revenues:
Premiums........................................................................................ 	$ 	63,896 	$ 	56,233 	$ 	127,966 	$ 	111,719
Products ......................................................................................... 	9,496 	8,433 	18,836 	16,773
Services.......................................................................................... 	6,645 	6,099 	13,017 	12,017
Investment and other income ................................................................ 	295 	556 	662 	1,008
Total revenues ........................................................................................ 	80,332 	71,321 	160,481 	141,517
Operating costs:
Medical costs ................................................................................... 	52,093 	46,546 	104,616 	91,450
Operating costs ................................................................................. 	11,709 	10,359 	23,110 	20,582
Cost of products sold .......................................................................... 	8,596 	7,660 	17,083 	15,232
Depreciation and amortization ............................................................... 	802 	778 	1,590 	1,536
Total operating costs ................................................................................ 	73,200 	65,343 	146,399 	128,800
Earnings from operations ........................................................................ 	7,132 	5,978 	14,082 	12,717
Interest expense ...................................................................................... 	(467) 	(410) 	(900) 	(807)
Earnings before income taxes ................................................................... 	6,665 	5,568 	13,182 	11,910
Provision for income taxes ......................................................................... 	(1,466) 	(1,196) 	(2,835) 	(2,560)
Net earnings ......................................................................................... 	5,199 	4,372 	10,347 	9,350
Earnings attributable to noncontrolling interests................................................ 	(129) 	(106) 	(250) 	(222)
Net earnings attributable to UnitedHealth Group common shareholders ............ 	$ 	5,070 	$ 	4,266 	$ 	10,097 	$ 	9,128
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic ............................................................................................. 	$ 	5.41 	$ 	4.52 	$ 	10.75 	$ 	9.66
Diluted ........................................................................................... 	$ 	5.34 	$ 	4.46 	$ 	10.61 	$ 	9.55
Basic weighted-average number of common shares outstanding ....................... 	937 	944 	939 	945
Dilutive effect of common share equivalents ................................................ 	13 	12 	13 	11
Diluted weighted-average number of common shares outstanding .................... 	950 	956 	952 	956
Anti-dilutive shares excluded from the calculation of dilutive effect of common share
equivalents ......................................................................................... 	3 	1 	3 	2
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
(in millions) 	2022 	2021 	2022 	2021
Three Months Ended
June 30,
Six Months Ended
June 30,
Net earnings ................................................................................................. 	$ 	5,199 	$ 	4,372 	$ 	10,347 	$ 	9,350
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period ........... 	(1,331) 	251 	(3,354) 	(513)
Income tax effect ................................................................................ 	304 	(58) 	769 	116
Total unrealized (losses) gains, net of tax ............................................. 	(1,027) 	193 	(2,585) 	(397)
Gross reclassification adjustment for net realized gains included in net earnings .... 	(1) 	(9) 	(4) 	(16)
Income tax effect ................................................................................ 	— 	2 	1 	4
Total reclassification adjustment, net of tax .......................................... 	(1) 	(7) 	(3) 	(12)
Total foreign currency translation (losses) gains ........................................... 	(676) 	554 	242 	137
Other comprehensive (loss) income ................................................................ 	(1,704) 	740 	(2,346) 	(272)
Comprehensive income ..................................................................................... 	3,495 	5,112 	8,001 	9,078
Comprehensive income attributable to noncontrolling interests ..................................... 	(129) 	(106) 	(250) 	(222)
Comprehensive income attributable to UnitedHealth Group common shareholders ...... 	$ 	3,366 	$ 	5,006 	$ 	7,751 	$ 	8,856
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Three months ended June 30,
(in millions) 	Shares Amount
Additional
Paid-In
Capital Retained
Earnings
Net Unrealized
(Losses) Gains
on Investments
Foreign
Currency
Translation
(Losses) Gains
Nonredeemable
Noncontrolling
Interests Total
Equity
Common Stock
Accumulated Other
Comprehensive
(Loss) Income
Balance at March 31, 2022 .................... 	939 $ 	10 $ 	— $ 	78,782 $ 	(1,137) $ 	(4,889) $ 	3,362 $ 76,128
Net earnings...................................... 	5,070 	94 	5,164
Other comprehensive loss...................... 	(1,028) 	(676) 	(1,704)
Issuances of common stock, and related tax
effects .......................................... 	1 	— 	174 	174
Share-based compensation..................... 	194 	194
Common share repurchases.................... 	(5) 	— 	(733) 	(1,767) 	(2,500)
Cash dividends paid on common shares
($1.65 per share) ............................. 	(1,545) 	(1,545)
Redeemable noncontrolling interests fair
value and other adjustments ................ 	365 	365
Acquisition and other adjustments of
nonredeemable noncontrolling interests .. 	12 	12
Distribution to nonredeemable
noncontrolling interests ..................... 	(83) 	(83)
Balance at June 30, 2022 ...................... 	935 $ 	10 $ 	— $ 	80,540 $ 	(2,165) $ 	(5,565) $ 	3,385 $ 76,205
Balance at March 31, 2021 .................... 	944 $ 	10 $ 	— $ 	71,220 $ 	741 $ 	(5,567) $ 	2,909 $ 69,313
Net earnings...................................... 	4,266 	88 	4,354
Other comprehensive income ................. 	186 	554 	740
Issuances of common stock, and related tax
effects .......................................... 	2 	— 	292 	292
Share-based compensation..................... 	158 	158
Common share repurchases.................... 	(3) 	— 	(221) 	(1,029) 	(1,250)
Cash dividends paid on common shares
($1.45 per share) ............................. 	(1,367) 	(1,367)
Redeemable noncontrolling interests fair
value and other adjustments ................ 	(229) 	(229)
Acquisition and other adjustments of
nonredeemable noncontrolling interests .. 	85 	85
Distribution to nonredeemable
noncontrolling interests ..................... 	(74) 	(74)
Balance at June 30, 2021 ...................... 	943 $ 	10 $ 	— $ 	73,090 $ 	927 $ 	(5,013) $ 	3,008 $ 72,022
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Six months ended June 30,
(in millions) 	Shares Amount
Additional
Paid-In
Capital Retained
Earnings
Net Unrealized
Gains (Losses)
on Investments
Foreign
Currency
Translation
(Losses) Gains
Nonredeemable
Noncontrolling
Interests Total
Equity
Common Stock
Accumulated Other
Comprehensive
Income (Loss)
Balance at January 1, 2022 .................... 	941 $ 	10 $ 	— $ 	77,134 $ 	423 $ 	(5,807) $ 	3,285 $ 75,045
Net earnings...................................... 	10,097 	182 	10,279
Other comprehensive (loss) income.......... 	(2,588) 	242 	(2,346)
Issuances of common stock, and related tax
effects .......................................... 	4 	— 	507 	507
Share-based compensation..................... 	476 	476
Common share repurchases.................... 	(10) 	— 	(1,217) 	(3,783) 	(5,000)
Cash dividends paid on common shares
($3.10 per share) ............................. 	(2,908) 	(2,908)
Redeemable noncontrolling interests fair
value and other adjustments ................ 	234 	234
Acquisition and other adjustments of
nonredeemable noncontrolling interests .. 	103 	103
Distribution to nonredeemable
noncontrolling interests ..................... 	(185) 	(185)
Balance at June 30, 2022 ...................... 	935 $ 	10 $ 	— $ 	80,540 $ 	(2,165) $ 	(5,565) $ 	3,385 $ 76,205
Balance at January 1, 2021 .................... 	946 $ 	10 $ 	— $ 	69,295 $ 	1,336 $ 	(5,150) $ 	2,837 $ 68,328
Net earnings...................................... 	9,128 	168 	9,296
Other comprehensive (loss) income.......... 	(409) 	137 	(272)
Issuances of common stock, and related tax
effects .......................................... 	5 	— 	548 	548
Share-based compensation..................... 	400 	400
Common share repurchases.................... 	(8) 	— 	(221) 	(2,679) 	(2,900)
Cash dividends paid on common shares
($2.70 per share) ............................. 	(2,548) 	(2,548)
Redeemable noncontrolling interests fair
value and other adjustments ................ 	(727) 	(106) 	(833)
Acquisitions and other adjustments of
nonredeemable noncontrolling interests .. 	151 	151
Distribution to nonredeemable
noncontrolling interests ..................... 	(148) 	(148)
Balance at June 30, 2021 ...................... 	943 $ 	10 $ 	— $ 	73,090 $ 	927 $ 	(5,013) $ 	3,008 $ 72,022
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 29 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in millions) 	2022 	2021
Six Months Ended
June 30,
Operating activities
Net earnings ................................................................................................................................ 	$ 	10,347 	$ 	9,350
Noncash items:
Depreciation and amortization..................................................................................................... 	1,590 	1,536
Deferred income taxes .............................................................................................................. 	(15) 	327
Share-based compensation ......................................................................................................... 	504 	426
Other, net.............................................................................................................................. 	215 	(214)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable ................................................................................................................. 	(4,204) 	(1,218)
Other assets ........................................................................................................................... 	(643) 	(1,523)
Medical costs payable............................................................................................................... 	4,029 	3,086
Accounts payable and other liabilities ........................................................................................... 	807 	298
Unearned revenues .................................................................................................................. 	(440) 	(523)
Cash flows from operating activities ................................................................................................... 	12,190 	11,545
Investing activities
Purchases of investments ................................................................................................................. 	(8,903) 	(8,847)
Sales of investments....................................................................................................................... 	2,348 	1,408
Maturities of investments................................................................................................................. 	3,189 	4,650
Cash paid for acquisitions, net of cash assumed...................................................................................... 	(7,150) 	(4,642)
Purchases of property, equipment and capitalized software ........................................................................ 	(1,212) 	(1,130)
Other, net.................................................................................................................................... 	(532) 	(648)
Cash flows used for investing activities................................................................................................ 	(12,260) 	(9,209)
Financing activities
Common share repurchases .............................................................................................................. 	(5,000) 	(2,900)
Cash dividends paid ....................................................................................................................... 	(2,908) 	(2,548)
Proceeds from common stock issuances ............................................................................................... 	756 	764
Repayments of long-term debt........................................................................................................... 	(1,100) 	(1,900)
Proceeds from (repayments of) short-term borrowings, net ........................................................................ 	1,340 	(176)
Proceeds from issuance of long-term debt............................................................................................. 	5,922 	6,934
Customer funds administered ............................................................................................................ 	5,786 	2,395
Purchases of redeemable noncontrolling interests.................................................................................... 	(97) 	(1,338)
Other, net.................................................................................................................................... 	(1,449) 	(662)
Cash flows from financing activities ................................................................................................... 	3,250 	569
Effect of exchange rate changes on cash and cash equivalents .................................................................... 	57 	6
Increase in cash and cash equivalents ............................................................................................... 	3,237 	2,911
Cash and cash equivalents, beginning of period .................................................................................. 	21,375 	16,921
Cash and cash equivalents, end of period .......................................................................................... 	$ 	24,612 	$ 19,832
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 29 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. 	Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is
a health care and well-being company with a mission to help people live healthier lives and help make the health system work
better for everyone. Our two distinct, yet complementary business platforms—Optum and UnitedHealthcare—are working to
help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the
individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end
condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures
required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the
Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual
audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read
together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and
Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the
SEC (2021 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments
necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill.
Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters
that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in
earnings in the period in which the estimate is adjusted.
7

-- 9 of 29 --

2. 	Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
June 30, 2022
Debt securities—available-for-sale:
U.S. government and agency obligations ...................................................... 	$ 	3,808 	$ 	1 	$ 	(209) $ 	3,600
State and municipal obligations ................................................................. 	7,725 	25 	(381) 	7,369
Corporate obligations ............................................................................. 	22,080 	5 	(1,515) 	20,570
U.S. agency mortgage-backed securities ...................................................... 	6,275 	2 	(537) 	5,740
Non-U.S. agency mortgage-backed securities ................................................ 	2,926 	— 	(201) 	2,725
Total debt securities—available-for-sale ............................................................ 	42,814 	33 	(2,843) 	40,004
Debt securities—held-to-maturity:
U.S. government and agency obligations ...................................................... 	544 	— 	(11) 	533
State and municipal obligations ................................................................. 	29 	— 	(2) 	27
Corporate obligations ............................................................................. 	141 	— 	— 	141
Total debt securities—held-to-maturity .............................................................. 	714 	— 	(13) 	701
Total debt securities ..................................................................................... 	$ 	43,528 	$ 	33 	$ 	(2,856) $ 	40,705
December 31, 2021
Debt securities—available-for-sale:
U.S. government and agency obligations ...................................................... 	$ 	3,206 	$ 	23 	$ 	(31) $ 	3,198
State and municipal obligations ................................................................. 	6,829 	297 	(20) 	7,106
Corporate obligations ............................................................................. 	20,947 	372 	(145) 	21,174
U.S. agency mortgage-backed securities ...................................................... 	5,868 	88 	(55) 	5,901
Non-U.S. agency mortgage-backed securities ................................................ 	2,819 	42 	(23) 	2,838
Total debt securities—available-for-sale ............................................................ 	39,669 	822 	(274) 	40,217
Debt securities—held-to-maturity:
U.S. government and agency obligations ...................................................... 	511 	2 	(2) 	511
State and municipal obligations ................................................................. 	30 	2 	— 	32
Corporate obligations ............................................................................. 	100 	— 	— 	100
Total debt securities—held-to-maturity .............................................................. 	641 	4 	(2) 	643
Total debt securities ..................................................................................... 	$ 	40,310 	$ 	826 	$ 	(276) $ 	40,860
The Company held $3.4 billion and $3.5 billion of equity securities as of June 30, 2022 and December 31, 2021, respectively.
The Company’s investments in equity securities primarily consist of employee savings plan related investments, other venture
investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally,
the Company’s investments included $1.7 billion and $1.3 billion of equity method investments in operating businesses in the
health care sector as of June 30, 2022 and December 31, 2021, respectively. The allowance for credit losses on held-to-maturity
securities at June 30, 2022 and December 31, 2021 was not material.
8

-- 10 of 29 --

The amortized cost and fair value of debt securities as of June 30, 2022, by contractual maturity, were as follows:
(in millions)
Amortized
Cost
Fair
Value
Amortized
Cost
Fair
Value
Available-for-Sale 	Held-to-Maturity
Due in one year or less ................................................................................. 	$ 	3,439 	$ 	3,422 	$ 	385 	$ 	381
Due after one year through five years ............................................................... 	13,237 	12,672 	295 	288
Due after five years through ten years ............................................................... 	12,332 	11,213 	14 	13
Due after ten years ...................................................................................... 	4,605 	4,232 	20 	19
U.S. agency mortgage-backed securities ............................................................ 	6,275 	5,740 	— 	—
Non-U.S. agency mortgage-backed securities ...................................................... 	2,926 	2,725 	— 	—
Total debt securities .................................................................................... 	$ 	42,814 	$ 	40,004 	$ 	714 	$ 	701
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
(in millions)
Fair
Value
Gross
Unrealized
Losses
Fair
Value
Gross
Unrealized
Losses
Fair
Value
Gross
Unrealized
Losses
Less Than 12 Months 	12 Months or Greater 	Total
June 30, 2022
Debt securities—available-for-sale:
U.S. government and agency obligations ...................... 	$ 	2,921 	$ 	(152) $ 	474 	$ 	(57) $ 	3,395 	$ 	(209)
State and municipal obligations ................................. 	4,807 	(355) 	209 	(26) 	5,016 	(381)
Corporate obligations.............................................. 	16,894 	(1,200) 	2,261 	(315) 	19,155 	(1,515)
U.S. agency mortgage-backed securities ....................... 	4,323 	(356) 	1,201 	(181) 	5,524 	(537)
Non-U.S. agency mortgage-backed securities................. 	2,354 	(151) 	354 	(50) 	2,708 	(201)
Total debt securities—available-for-sale ............................. 	$ 	31,299 	$ 	(2,214) $ 	4,499 	$ 	(629) $ 	35,798 	$ 	(2,843)
December 31, 2021
Debt securities—available-for-sale:
U.S. government and agency obligations ...................... 	$ 	1,976 	$ 	(18) $ 	249 	$ 	(13) $ 	2,225 	$ 	(31)
State and municipal obligations ................................. 	1,386 	(19) 	31 	(1) 	1,417 	(20)
Corporate obligations.............................................. 	9,357 	(130) 	376 	(15) 	9,733 	(145)
U.S. agency mortgage-backed securities ....................... 	3,078 	(52) 	116 	(3) 	3,194 	(55)
Non-U.S. agency mortgage-backed securities................. 	1,321 	(18) 	114 	(5) 	1,435 	(23)
Total debt securities—available-for-sale ............................. 	$ 	17,118 	$ 	(237) $ 	886 	$ 	(37) $ 	18,004 	$ 	(274)
The Company’s unrealized losses from debt securities as of June 30, 2022 were generated from approximately 33,000 positions
out of a total of 40,000 positions. The Company believes that it will collect the timely principal and interest due on its debt
securities that have an amortized cost in excess of fair value. The unrealized losses were caused by interest rate increases and
not by unfavorable changes in the credit quality associated with these securities that impacted the Company’s assessment on
collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any
credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the
expected cash flows, the underlying credit quality and credit ratings of the issuers noting no significant credit deterioration since
purchase. As of June 30, 2022, the Company did not have the intent to sell any of the available-for-sale debt securities in an
unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on
available-for-sale debt securities at June 30, 2022 and December 31, 2021 was not material.
9

-- 11 of 29 --

3. 	Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in
Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
June 30, 2022
Cash and cash equivalents ...................................................................... 	$ 	24,546 	$ 	66 	$ 	— 	$ 24,612
Debt securities—available-for-sale:
U.S. government and agency obligations .............................................. 	3,432 	168 	— 	3,600
State and municipal obligations ......................................................... 	— 	7,369 	— 	7,369
Corporate obligations...................................................................... 	35 	20,342 	193 	20,570
U.S. agency mortgage-backed securities ............................................... 	— 	5,740 	— 	5,740
Non-U.S. agency mortgage-backed securities......................................... 	— 	2,725 	— 	2,725
Total debt securities—available-for-sale ..................................................... 	3,467 	36,344 	193 	40,004
Equity securities.................................................................................. 	1,894 	18 	68 	1,980
Assets under management ...................................................................... 	1,655 	2,268 	94 	4,017
Total assets at fair value ........................................................................ 	$ 	31,562 	$ 38,696 	$ 	355 	$ 70,613
Percentage of total assets at fair value........................................................ 	45% 	54% 	1% 	100%
December 31, 2021
Cash and cash equivalents ...................................................................... 	$ 	21,359 	$ 	16 	$ 	— 	$ 21,375
Debt securities—available-for-sale:
U.S. government and agency obligations .............................................. 	3,017 	181 	— 	3,198
State and municipal obligations ......................................................... 	— 	7,106 	— 	7,106
Corporate obligations...................................................................... 	40 	20,916 	218 	21,174
U.S. agency mortgage-backed securities ............................................... 	— 	5,901 	— 	5,901
Non-U.S. agency mortgage-backed securities......................................... 	— 	2,838 	— 	2,838
Total debt securities—available-for-sale ..................................................... 	3,057 	36,942 	218 	40,217
Equity securities.................................................................................. 	2,090 	23 	64 	2,177
Assets under management ...................................................................... 	1,972 	2,376 	101 	4,449
Total assets at fair value ........................................................................ 	$ 	28,478 	$ 39,357 	$ 	383 	$ 68,218
Percentage of total assets at fair value........................................................ 	42% 	57% 	1% 	100%
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2022 or 2021.
10

-- 12 of 29 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
June 30, 2022
Debt securities—held-to-maturity ................................................ 	$ 	597 	$ 	104 	$ 	— 	$ 	701 	$ 	714
Long-term debt and other financing obligations ............................... 	$ 	— 	$ 	48,549 	$ 	— 	$48,549 	$50,041
December 31, 2021
Debt securities—held-to-maturity ................................................ 	$ 	534 	$ 	102 	$ 	7 	$ 	643 	$ 	641
Long-term debt and other financing obligations ............................... 	$ 	— 	$ 	52,583 	$ 	— 	$52,583 	$46,003
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were
no significant fair value adjustments for these assets and liabilities recorded during either the six months ended June 30, 2022 or
2021.
4. 	Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions) 	2022 	2021
Medical costs payable, beginning of period ........................................................................................... 	$ 24,483 	$ 21,872
Acquisitions ................................................................................................................................. 	171 	46
Reported medical costs:
Current year........................................................................................................................... 	104,936 	92,570
Prior years ............................................................................................................................. 	(320) 	(1,120)
Total reported medical costs ............................................................................................................. 	104,616 	91,450
Medical payments:
Payments for current year .......................................................................................................... 	(78,937) 	(69,808)
Payments for prior years ............................................................................................................ 	(21,355) 	(18,429)
Total medical payments................................................................................................................... 	(100,292) 	(88,237)
Medical costs payable, end of period ................................................................................................... 	$ 28,978 	$ 25,131
For the six months ended June 30, 2022, prior years’ medical cost reserve development included no individual factors that were
significant. For the six months ended June 30, 2021, prior years’ medical cost reserve development was primarily driven by
lower than expected health system utilization and the uncertainty of care patterns due to the disruption of the health care system
caused by COVID-19. Medical costs payable included reserves for claims incurred by insured customers but not yet reported to
the Company of $20.3 billion and $17.1 billion at June 30, 2022 and December 31, 2021, respectively.
5. 	Short-Term Borrowings and Long-Term Debt
In May 2022, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages) 	Par Value
3.700% notes due May 2027............................................................................................................................. 	$ 	600
4.000% notes due May 2029............................................................................................................................. 	900
4.200% notes due May 2032............................................................................................................................. 	1,500
4.750% notes due May 2052............................................................................................................................. 	2,000
4.950% notes due May 2062............................................................................................................................. 	1,000
11

-- 13 of 29 --

For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K.
6. 	Dividends
In June 2022, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual
rate of $6.60 compared to $5.80 per share, which the Company had paid since June 2021. Declaration and payment of future
quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions
change.
The following table provides details of the Company’s 2022 dividend payments:
Payment Date 	Amount per Share 	Total Amount Paid
(in millions)
March 22................................................................................................................ 	$ 	1.45 	$ 	1,363
June 28 .................................................................................................................. 	1.65 	1,545
7. 	Commitments and Contingencies
Pending Business Combinations
As of June 30, 2022, the Company has entered into agreements to acquire companies in the health care sector, most notably
Change Healthcare (NASDAQ: CHNG) and LHC Group, Inc (NASDAQ: LHCG), subject to regulatory approval and other
customary closing conditions. The total anticipated capital required for these business combinations, excluding associated
disposition proceeds and the payoff of acquired indebtedness, is approximately $14 billion.
Legal Matters
Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory
inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers
and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and
other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract
claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where
the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present
novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the
early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to
estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may
be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the
Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the DOJ, the SEC, the Internal Revenue Service, the U.S. Drug Enforcement
Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection
Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses
are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other
12

-- 14 of 29 --

non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review,
including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model.
CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding
practices of and supporting documentation maintained by health care providers and such audits may result in retrospective
adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the
Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15,
2017, alleges that the Company made improper Medicare risk adjustment submissions and violated the False Claims Act. On
February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved
to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March
2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims
without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural
status.
8. 	Business Combinations
During the six months ended June 30, 2022, the Company completed several business combinations for total consideration of
$8.1 billion.
Acquired assets (liabilities) at acquisition date were:
(in millions)
Cash and cash equivalents ...................................................................................................................... 	$ 	457
Accounts receivable and other current assets ................................................................................................ 	585
Property, equipment and other long-term assets............................................................................................. 	1,494
Intangible assets .................................................................................................................................. 	1,810
Total identifiable assets acquired ........................................................................................................ 	4,346
Medical costs payable ........................................................................................................................... 	(171)
Accounts payable and other current liabilities............................................................................................... 	(590)
Other long-term liabilities....................................................................................................................... 	(605)
Total identifiable liabilities acquired .................................................................................................... 	(1,366)
Total net identifiable assets......................................................................................................... 	2,980
Goodwill ........................................................................................................................................... 	8,309
Redeemable noncontrolling interests .......................................................................................................... 	(3,101)
Nonredeemable noncontrolling interests...................................................................................................... 	(103)
Net assets acquired ................................................................................................................... 	$ 	8,085
The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various
business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent
liabilities, are finalized.
The acquisition date fair values and weighted-average useful lives assigned to finite-lived intangible assets were:
(in millions, except years) Fair
Value
Weighted-
Average
Useful Life
Customer-related ............................................................................................................................. 	$ 915 	9 years
Trademarks and technology ................................................................................................................ 	800 	9 years
Other ........................................................................................................................................... 	80 	11 years
Total acquired finite-lived intangible assets ............................................................................................. 	$1,795 	9 years
13

-- 15 of 29 --

The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results
and the results of the corresponding operating segment as of the date of acquisition. Through June 30, 2022, acquired entities
impact on revenues and net earnings was not material.
Unaudited pro forma revenues and net earnings for the six months ended June 30, 2022 and 2021 as if the business
combinations had occurred on January 1, 2021 were immaterial for both periods.
9. 	Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more
information on the Company’s segments, see Part I, Item I, “Business” and Note 13 of Notes to the Consolidated Financial
Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2021 10-K. Total assets at Optum
Health and Optum Rx increased to $67.9 billion and $46.2 billion as of June 30, 2022 compared to $60.5 billion and $40.2
billion as of December 31, 2021, respectively. The increase in total assets at Optum Health and Optum Rx was primarily due to
goodwill from business combinations of $4.5 billion and $3.8 billion, respectively.
On January 1, 2022, the Company realigned its operating segments to combine UnitedHealthcare Global and UnitedHealthcare
Employer & Individual. The realignment had no impact on the Company’s reportable segments.
The following tables present reportable segment financial information:
(in millions) 	UnitedHealthcare Optum Health Optum Insight Optum Rx
Optum
Eliminations 	Optum
Corporate and
Eliminations Consolidated
Optum
Three Months Ended June 30, 2022
Revenues—unaffiliated customers:
Premiums .................................. $ 	59,368 	$ 	4,528 	$ 	— $ 	— $ 	— $ 4,528 $ 	— $ 	63,896
Products.................................... 	— 	6 	58 	9,432 	— 	9,496 	— 	9,496
Services .................................... 	2,542 	2,740 	1,034 	329 	— 	4,103 	— 	6,645
Total revenues—unaffiliated customers .... 	61,910 	7,274 	1,092 	9,761 	— 	18,127 	— 	80,037
Total revenues—affiliated customers ....... 	— 	10,224 	2,181 	15,038 	(588) 	26,855 	(26,855) 	—
Investment and other income................. 	195 	85 	9 	6 	— 	100 	— 	295
Total revenues .................................. $ 	62,105 	$ 	17,583 	$ 	3,282 $ 24,805 $ 	(588) $45,082 $ 	(26,855) $ 	80,332
Earnings from operations ..................... $ 	3,850 	$ 	1,399 	$ 	839 $ 	1,044 $ 	— $ 3,282 $ 	— $ 	7,132
Interest expense................................. 	— 	— 	— 	— 	— 	— 	(467) 	(467)
Earnings before income taxes ................ $ 	3,850 	$ 	1,399 	$ 	839 $ 	1,044 $ 	— $ 3,282 $ 	(467) $ 	6,665
Three Months Ended June 30, 2021
Revenues—unaffiliated customers:
Premiums .................................. $ 	52,858 	$ 	3,375 	$ 	— $ 	— $ 	— $ 3,375 $ 	— $ 	56,233
Products.................................... 	— 	9 	33 	8,391 	— 	8,433 	— 	8,433
Services .................................... 	2,440 	2,461 	930 	268 	— 	3,659 	— 	6,099
Total revenues—unaffiliated customers .... 	55,298 	5,845 	963 	8,659 	— 	15,467 	— 	70,765
Total revenues—affiliated customers ....... 	— 	7,221 	1,921 	13,792 	(478) 	22,456 	(22,456) 	—
Investment and other income................. 	176 	234 	73 	73 	— 	380 	— 	556
Total revenues .................................. $ 	55,474 	$ 	13,300 	$ 	2,957 $ 22,524 $ 	(478) $38,303 $ 	(22,456) $ 	71,321
Earnings from operations ..................... $ 	3,095 	$ 	1,128 	$ 	762 $ 	993 $ 	— $ 2,883 $ 	— $ 	5,978
Interest expense................................. 	— 	— 	— 	— 	— 	— 	(410) 	(410)
Earnings before income taxes ................ $ 	3,095 	$ 	1,128 	$ 	762 $ 	993 $ 	— $ 2,883 $ 	(410) $ 	5,568
14

-- 16 of 29 --

(in millions) 	UnitedHealthcare Optum Health Optum Insight Optum Rx
Optum
Eliminations 	Optum
Corporate and
Eliminations 	Consolidated
Optum
Six Months Ended June 30, 2022
Revenues—unaffiliated customers:
Premiums ................................ $ 	119,305 $ 	8,661 	$ 	— $ 	— $ 	— $ 8,661 $ 	— $ 	127,966
Products .................................. 	— 	12 	98 	18,726 	— 	18,836 	— 	18,836
Services .................................. 	5,057 	5,298 	2,008 	654 	— 	7,960 	— 	13,017
Total revenues—unaffiliated customers .. 	124,362 	13,971 	2,106 	19,380 	— 	35,457 	— 	159,819
Total revenues—affiliated customers ..... 	— 	20,053 	4,319 	29,329 	(1,141) 	52,560 	(52,560) 	—
Investment and other income ............... 	338 	241 	76 	7 	— 	324 	— 	662
Total revenues................................. $ 	124,700 $ 	34,265 	$ 	6,501 $ 48,716 $ (1,141) $88,341 $ 	(52,560) $ 	160,481
Earnings from operations.................... $ 	7,648 $ 	2,765 	$ 	1,686 $ 	1,983 $ 	— $ 6,434 $ 	— $ 	14,082
Interest expense ............................... 	— 	— 	— 	— 	— 	— 	(900) 	(900)
Earnings before income taxes .............. $ 	7,648 $ 	2,765 	$ 	1,686 $ 	1,983 $ 	— $ 6,434 $ 	(900) $ 	13,182
Six Months Ended June 30, 2021
Revenues—unaffiliated customers:
Premiums ................................ $ 	105,416 $ 	6,303 	$ 	— $ 	— $ 	— $ 6,303 $ 	— $ 	111,719
Products .................................. 	— 	17 	70 	16,686 	— 	16,773 	— 	16,773
Services .................................. 	4,790 	4,797 	1,891 	539 	— 	7,227 	— 	12,017
Total revenues—unaffiliated customers .. 	110,206 	11,117 	1,961 	17,225 	— 	30,303 	— 	140,509
Total revenues—affiliated customers ..... 	— 	14,173 	3,742 	26,796 	(953) 	43,758 	(43,758) 	—
Investment and other income ............... 	382 	413 	106 	107 	— 	626 	— 	1,008
Total revenues................................. $ 	110,588 $ 	25,703 	$ 	5,809 $ 44,128 $ 	(953) $74,687 $ 	(43,758) $ 	141,517
Earnings from operations.................... $ 	7,203 $ 	2,090 	$ 	1,541 $ 	1,883 $ 	— $ 5,514 $ 	— $ 	12,717
Interest expense ............................... 	— 	— 	— 	— 	— 	— 	(807) 	(807)
Earnings before income taxes .............. $ 	7,203 $ 	2,090 	$ 	1,541 $ 	1,883 $ 	— $ 5,514 $ 	(807) $ 	11,910
15

-- 17 of 29 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2021 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,
“Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms
“UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of
Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management’s Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking
statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2021 10-K
and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group Incorporated is a health care and well-being company with a mission to help people live healthier lives and
help make the health system work better for everyone. Our two distinct, yet complementary business platforms—Optum and
UnitedHealthcare—are working to help build a modern, high-performing health system through improved access, affordability,
outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments across our two business platforms, Optum and UnitedHealthcare:
• 	Optum Health;
• 	Optum Insight;
• 	Optum Rx; and
• 	UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and
UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2021 10-K and additional information on our segments,
including the realignment of our UnitedHealthcare operating segments to combine UnitedHealthcare Global and
UnitedHealthcare Employer and Individual, can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated
Financial Statements included in Part I, Item 1 of this report.
Business Trends
Our businesses participate in the United States, South America and certain other international health markets. Overall spending
on health care is impacted by inflation, utilization, medical technology and pharmaceutical advancement, regulatory
requirements, demographic trends in the populaton and national interest in health and well-being. The rate of market growth
may be affected by a variety of factors, including macroeconomic conditions, such as the economic impact of COVID-19, and
regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefit products, we start with our view of expected future costs, including any
potential impacts from COVID-19. We frequently evaluate and adjust our approach in each of the local markets we serve,
considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative
16

-- 18 of 29 --

and regulatory considerations, including minimum medical loss ratio (MLR) thresholds and similar revenue adjustments. We
will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect
broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market
due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, health system utilization and
prescription drug costs. COVID-19 related care and testing costs as well as the deferral of care have also impacted medical cost
trends in the current year and may continue in future years. Future medical cost trends may be impacted by increased consumer
demand for care, and potentially even higher acuity care, due to the temporary deferral of care since the onset of the pandemic.
We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make
clinically sound choices, with the objective of helping them achieve high-quality, affordable care. The continued uncertain
impact of COVID-19 may impact our ability to estimate medical costs payable, which has resulted in, and could result in,
increased variability to medical cost reserve development.
COVID-19 Trends and Uncertainties
The COVID-19 pandemic continues to evolve and the ultimate impact on our business, results of operations, financial condition
and cash flows remains uncertain. During the six months ended June 30, 2022, overall care was near normal baseline levels,
with certain areas of care at or approaching seasonal baselines, and other areas below. COVID-19 treatment and testing costs
continue to be mitigated by the temporary deferral of care, both generally varying with COVID-19 incidence rates. The
relationship between COVID-19 care costs and non-COVID-19 utilization lagged in the second quarter, with increased non-
COVID-19 utilization not as rapidly coinciding with decreased COVID-19 care and incidence rates as it had throughout the
pandemic. In future periods, care patterns may moderately exceed normal baselines as previously deferred care is obtained.
Though not yet experienced, acuity may temporarily rise due to missed regular care.
COVID-19 may continue to influence customer and consumer behavior, which could impact how and where care is delivered,
benefit product designs, and the manner in which consumers wish to receive their prescription drugs or infusion services.
Disrupted care patterns, as a result of the pandemic, have affected and may continue to temporarily affect the ability to obtain
complete member health status information, impacting revenue in businesses utilizing risk adjustment methodologies.
The ultimate overall impact is uncertain and dependent on the future pacing, intensity and duration of the pandemic, the severity
of new variants of the COVID-19 virus, the effectiveness and extent of administration of vaccination and treatments and general
economic uncertainty.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2022 year-over-year operating comparisons to second quarter 2021 and other
financial results.
• 	Consolidated revenues grew 13%, UnitedHealthcare revenues grew 12% and Optum revenues grew 18%.
• 	UnitedHealthcare served 1.6 million more people, led by growth in community and senior programs.
• 	Consolidated earnings from operations of $7.1 billion compared to $6.0 billion last year, included growth of 24% at
UnitedHealthcare and 14% at Optum.
• 	Diluted earnings per common share were $5.34.
• 	Cash flows from operations for the six months ended June 30, 2022 were $12.2 billion.
• 	Return on equity was 27.9%.
17

-- 19 of 29 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data) 	2022 	2021 	2022 vs. 2021 	2022 	2021 	2022 vs. 2021
Three Months Ended
June 30,
Increase/
(Decrease)
Six Months Ended
June 30,
Increase/
(Decrease)
Revenues:
Premiums........................................... $ 	63,896 $ 	56,233 $ 	7,663 	14% $ 	127,966 $ 	111,719 $ 	16,247 	15%
Products ............................................ 	9,496 	8,433 	1,063 	13 	18,836 	16,773 	2,063 	12
Services............................................. 	6,645 	6,099 	546 	9 	13,017 	12,017 	1,000 	8
Investment and other income ................... 	295 	556 	(261) (47) 	662 	1,008 	(346) (34)
Total revenues ........................................... 	80,332 	71,321 	9,011 	13 	160,481 	141,517 	18,964 	13
Operating costs:
Medical costs ...................................... 	52,093 	46,546 	5,547 	12 	104,616 	91,450 	13,166 	14
Operating costs .................................... 	11,709 	10,359 	1,350 	13 	23,110 	20,582 	2,528 	12
Cost of products sold ............................. 	8,596 	7,660 	936 	12 	17,083 	15,232 	1,851 	12
Depreciation and amortization.................. 	802 	778 	24 	3 	1,590 	1,536 	54 	4
Total operating costs ................................... 	73,200 	65,343 	7,857 	12 	146,399 	128,800 	17,599 	14
Earnings from operations .............................. 	7,132 	5,978 	1,154 	19 	14,082 	12,717 	1,365 	11
Interest expense ......................................... 	(467) 	(410) 	(57) 	14 	(900) 	(807) 	(93) 	12
Earnings before income taxes......................... 	6,665 	5,568 	1,097 	20 	13,182 	11,910 	1,272 	11
Provision for income taxes ............................ 	(1,466) 	(1,196) 	(270) 	23 	(2,835) 	(2,560) 	(275) 	11
Net earnings ............................................. 	5,199 	4,372 	827 	19 	10,347 	9,350 	997 	11
Earnings attributable to noncontrolling interests... 	(129) 	(106) 	(23) 	22 	(250) 	(222) 	(28) 	13
Net earnings attributable to UnitedHealth Group
common shareholders ............................... $ 	5,070 $ 	4,266 $ 	804 	19% $ 	10,097 $ 	9,128 $ 	969 	11%
Diluted earnings per share attributable to
UnitedHealth Group common shareholders ..... $ 	5.34 $ 	4.46 $ 	0.88 	20% $ 	10.61 $ 	9.55 $ 	1.06 	11%
Medical care ratio (a) .................................. 	81.5% 	82.8% 	(1.3)% 	81.8% 	81.9% 	(0.1)%
Operating cost ratio..................................... 	14.6 	14.5 	0.1 	14.4 	14.5 	(0.1)
Operating margin ....................................... 	8.9 	8.4 	0.5 	8.8 	9.0 	(0.2)
Tax rate ................................................... 	22.0 	21.5 	0.5 	21.5 	21.5 	—
Net earnings margin (b)................................ 	6.3 	6.0 	0.3 	6.3 	6.5 	(0.2)
Return on equity (c) .................................... 	27.9% 	25.2% 	2.7% 	27.9% 	27.3% 	0.6%
(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity.
Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at
the end of each of the quarters in the year presented.
2022 RESULTS OF OPERATIONS COMPARED TO 2021 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in the number of people served through Medicare Advantage,
Medicaid and commercial offerings; pricing trends; and growth across the Optum businesses.
18

-- 20 of 29 --

Medical Costs and MCR
Medical costs increased due to growth in people served through Medicare Advantage, Medicaid and commercial offerings. For
the three months ended June 30, 2022, MCR decreased due to COVID-19 effects and business mix. For the six months ended
June 30, 2022, MCR decreased as a result of COVID-19 effects offset by business mix and decreased prior years favorable
development, primarily due to the effects of COVID-19 in 2021.
Operating Cost Ratio
For the three months ended June 30, 2022, the operating cost ratio increased primarily due to business mix and investments,
partially offset by COVID-19 related revenue effects. For the six months ended June 30, 2022, the operating cost ratio decreased
as a result of COVID-19 related revenue effects, partially offset by business mix.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people
served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted
scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, including the mix of care delivered through value-
based care models at Optum Health, level and scope of services provided to people and pricing trends when comparing the
metrics to revenue by segment.
The following table presents a summary of the reportable segment financial information:
(in millions, except percentages) 	2022 	2021 	2022 vs. 2021 	2022 	2021 	2022 vs. 2021
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
Revenues
UnitedHealthcare .................................... 	$ 	62,105 	$ 	55,474 	$ 	6,631 	12% $ 	124,700 	$ 	110,588 	$ 	14,112 	13%
Optum Health .................................. 	17,583 	13,300 	4,283 	32 	34,265 	25,703 	8,562 	33
Optum Insight .................................. 	3,282 	2,957 	325 	11 	6,501 	5,809 	692 	12
Optum Rx....................................... 	24,805 	22,524 	2,281 	10 	48,716 	44,128 	4,588 	10
Optum eliminations ........................... 	(588) 	(478) 	(110) 	23 	(1,141) 	(953) 	(188) 	20
Optum ................................................. 	45,082 	38,303 	6,779 	18 	88,341 	74,687 	13,654 	18
Eliminations .......................................... 	(26,855) 	(22,456) 	(4,399) 	20 	(52,560) 	(43,758) 	(8,802) 	20
Consolidated revenues .............................. 	$ 	80,332 	$ 	71,321 	$ 	9,011 	13% $ 	160,481 	$ 	141,517 	$ 	18,964 	13%
Earnings from operations
UnitedHealthcare .................................... 	$ 	3,850 	$ 	3,095 	$ 	755 	24% $ 	7,648 	$ 	7,203 	$ 	445 	6%
Optum Health .................................. 	1,399 	1,128 	271 	24 	2,765 	2,090 	675 	32
Optum Insight .................................. 	839 	762 	77 	10 	1,686 	1,541 	145 	9
Optum Rx....................................... 	1,044 	993 	51 	5 	1,983 	1,883 	100 	5
Optum ................................................. 	3,282 	2,883 	399 	14 	6,434 	5,514 	920 	17
Consolidated earnings from operations .......... 	$ 	7,132 	$ 	5,978 	$ 	1,154 	19% $ 	14,082 	$ 	12,717 	$ 	1,365 	11%
Operating margin
UnitedHealthcare .................................... 	6.2% 	5.6% 	0.6% 	6.1% 	6.5% 	(0.4)%
Optum Health .................................. 	8.0 	8.5 	(0.5) 	8.1 	8.1 	—
Optum Insight .................................. 	25.6 	25.8 	(0.2) 	25.9 	26.5 	(0.6)
Optum Rx....................................... 	4.2 	4.4 	(0.2) 	4.1 	4.3 	(0.2)
Optum ................................................. 	7.3 	7.5 	(0.2) 	7.3 	7.4 	(0.1)
Consolidated operating margin .................... 	8.9% 	8.4% 	0.5% 	8.8% 	9.0% 	(0.2)%
19

-- 21 of 29 --

UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
(in millions, except percentages) 	2022 	2021 	2022 vs. 2021 	2022 	2021 	2022 vs. 2021
Three Months Ended
June 30,
Increase/
(Decrease)
Six Months Ended
June 30,
Increase/
(Decrease)
UnitedHealthcare Employer & Individual — Domestic ..... $ 	15,567 $ 	14,942 $ 	625 	4% $ 31,389 $ 29,574 $ 	1,815 	6%
UnitedHealthcare Employer & Individual — Global (a) .... 	2,247 	2,118 	129 	6 	4,380 	4,153 	227 	5
UnitedHealthcare Employer & Individual — Total (a) 	17,814 	17,060 	754 	4 	35,769 	33,727 	2,042 	6
UnitedHealthcare Medicare & Retirement ..................... 	28,625 	25,304 	3,321 13 	57,725 	50,778 	6,947 14
UnitedHealthcare Community & State.......................... 	15,666 	13,110 	2,556 19 	31,206 	26,083 	5,123 20
Total UnitedHealthcare revenues .......................... $ 	62,105 $ 	55,474 $ 	6,631 12% $ 124,700 $ 110,588 $ 14,112 13%
(a) On January 1, 2022, we realigned our operating segments to combine UnitedHealthcare Global and UnitedHealthcare Employer & Individual.
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and
funding arrangement:
(in thousands, except percentages) 	2022 	2021 	2022 vs. 2021
June 30, Increase/
(Decrease)
Commercial — domestic:
Risk-based........................................................................................................... 	8,010 	7,840 	170 	2%
Fee-based ............................................................................................................ 	18,480 	18,395 	85 	—
Total commercial — domestic................................................................................ 	26,490 	26,235 	255 	1
Medicare Advantage.................................................................................................. 	6,945 	6,385 	560 	9
Medicaid................................................................................................................ 	7,990 	7,130 	860 	12
Medicare Supplement (Standardized).............................................................................. 	4,355 	4,390 	(35) 	(1)
Total community and senior................................................................................... 	19,290 	17,905 	1,385 	8
Total UnitedHealthcare — domestic medical .............................................................. 	45,780 	44,140 	1,640 	4
Commercial — global ................................................................................................ 	5,465 	5,485 	(20) 	—
Total UnitedHealthcare — medical .......................................................................... 	51,245 	49,625 	1,620 	3%
Supplemental Data:
Medicare Part D stand-alone .................................................................................. 	3,330 	3,750 	(420) (11)%
Commercial business increased primarily due to organic growth and business combinations. Medicare Advantage increased due
to growth in people served through individual and group Medicare Advantage plans. The increase in people served through
Medicaid was primarily driven by states continuing to ease redetermination requirements due to COVID-19, new state-based
awards and growth in people served through Dual Special Needs Plans.
UnitedHealthcare’s revenues increased due to growth in the number of individuals served through Medicare Advantage and
Medicaid, including a greater mix of people with higher acuity needs, and an increase in the number of individuals served
through commercial benefits. For the three months ended June 30, 2022, earnings from operations increased due growth in
people served and COVID-19 effects. For the six months ended June 30, 2022, earnings from operations increased due to
growth in people served and COVID-19 effects, partially offset by decreased prior years favorable development, primarily due
to the effects of COVID-19 in 2021.
20

-- 22 of 29 --

Optum
Total revenues and earnings from operations increased due to growth across the Optum businesses. The results by segment were
as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in value-based care arrangements and business
combinations. Earnings from operations increased due to organic growth in value-based care arrangements, cost management
initiatives and COVID-19 effects. Optum Health served approximately 101 million people as of June 30, 2022 compared to 99
million people as of June 30, 2021.
Optum Insight
Revenues and earnings from operations at Optum Insight increased due to growth in managed services and technology, with
managed services growth driven by higher payer volumes and new health system partnerships.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to higher script volumes from growth in people served,
increased utilization and organic growth in pharmacy care services, including community-behavioral and specialty pharmacy.
Earnings from operations also increased as a result of continued supply chain management initiatives. Optum Rx fulfilled 357
million and 342 million adjusted scripts in the second quarters of 2022 and 2021, respectively.
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
(in millions) 	2022 	2021 	2022 vs. 2021
Six Months Ended
June 30,
Increase/
(Decrease)
Sources of cash:
Cash provided by operating activities............................................................. 	$ 	12,190 	$ 	11,545 	$ 	645
Issuances of short-term borrowings and long-term debt, net of repayments ............... 	6,162 	4,858 	1,304
Proceeds from common stock issuances.......................................................... 	756 	764 	(8)
Customer funds administered ...................................................................... 	5,786 	2,395 	3,391
Total sources of cash ...................................................................................... 	24,894 	19,562
Uses of cash:
Common stock repurchases......................................................................... 	(5,000) 	(2,900) 	(2,100)
Cash paid for acquisitions, net of cash assumed ................................................ 	(7,150) 	(4,642) 	(2,508)
Purchases of investments, net of sales and maturities.......................................... 	(3,366) 	(2,789) 	(577)
Purchases of property, equipment and capitalized software................................... 	(1,212) 	(1,130) 	(82)
Cash dividends paid.................................................................................. 	(2,908) 	(2,548) 	(360)
Purchases of redeemable noncontrolling interests .............................................. 	(97) 	(1,338) 	1,241
Other ................................................................................................... 	(1,981) 	(1,310) 	(671)
Total uses of cash .......................................................................................... 	(21,714) 	(16,657)
Effect of exchange rate changes on cash and cash equivalents ..................................... 	57 	6 	51
Net increase in cash and cash equivalents.............................................................. 	$ 	3,237 	$ 	2,911 	$ 	326
21

-- 23 of 29 --

2022 Cash Flows Compared to 2021 Cash Flows
Increased cash flows provided by operating activities were primarily driven by increased net earnings partially offset by changes
in working capital accounts. Other significant changes in sources or uses of cash year-over-year included increased customer
funds administered, primarily driven by Medicare Part D timing, net issuances of short-term borrowings and long-term debt and
decreased purchases of redeemable noncontrolling interests, partially offset by increased cash paid for acquisitions and share
repurchases.
Financial Condition
As of June 30, 2022, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $68.0 billion
included approximately $24.6 billion of cash and cash equivalents (of which $1.7 billion was available for general corporate
use), $40.0 billion of debt securities and $3.4 billion of investments in equity securities. Given the significant portion of our
portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to
have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-
average duration of 4.1 years and a weighted-average credit rating of “Double A” as of June 30, 2022. When multiple credit
ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average
credit rating.
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2021 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 10-K. During the six
months ended June 30, 2022, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2021 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to
debt-plus-shareholders’ equity ratio of not more than 60%. As of June 30, 2022, our debt to debt-plus-shareholders’ equity ratio,
as defined and calculated under the credit facilities, was approximately 37%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as, to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of
this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2021 10-K.
Credit Ratings. Our credit ratings as of June 30, 2022 were as follows:
Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook 	Ratings 	Outlook
Moody’s 	S&P Global 	Fitch 	A.M. Best
Senior unsecured debt ........................................ 	A3 	Positive 	A+ 	Stable 	A 	Stable 	A 	Stable
Commercial paper ............................................. 	P-2 	n/a 	A-1 	n/a 	F1 	n/a 	AMB-1+ 	n/a
22

-- 24 of 29 --

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the six months ended June 30, 2022, we repurchased approximately 10 million shares at an
average price of $492.11 per share. As of June 30, 2022, we had Board of Directors’ authorization to purchase up to 35 million
shares of our common stock.
Dividends. In June 2022, the Company’s Board of Directors increased our quarterly cash dividend to shareholders to an annual
rate of $6.60 compared to $5.80 per share. For more information on our dividend, see Note 6 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Business Combinations. As of June 30, 2022, we have entered into agreements to acquire companies in the health care
sector, most notably Change Healthcare (NASDAQ: CHNG) and LHC Group, Inc. (NASDAQ: LHCG), subject to regulatory
approval and other customary closing conditions. The total anticipated capital required for these business combinations,
excluding associated disposition proceeds and the payoff of acquired indebtedness, is approximately $14 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” included in Part II, Item 7 in our 2021 10-K.
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting
estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II,
Item 7 in our 2021 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated
Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2021 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities law. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending
on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and
pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or
changes in existing health care laws or regulations, or their enforcement or application; the DOJ’s legal action relating to the
risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue;
23

-- 25 of 29 --

reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings
program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information
systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our
failure to comply with related regulations; failure to protect proprietary rights to our databases, software and related products;
risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our
ability to develop and deliver innovative products to health care payers and expand access to virtual care; changes in or
challenges to our public sector contract awards; failure to develop and maintain satisfactory relationships with health care
payers, physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key
employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S.
income tax rate applicable to corporations); failure to achieve targeted operating cost productivity improvements; increases in
costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully
our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency
exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and
intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund
our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or
continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks
that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC,
including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future
performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual
results may vary materially from expectations expressed or implied in this document or any of our prior communications. You
should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not
undertake to update or revise any forward-looking statements, except as required by law.
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of June 30, 2022 on our investment income and interest expense per annum, and the fair value of our
investments and debt (in millions, except percentages):
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum
Interest
Expense Per
Annum Fair Value of
Financial Assets Fair Value of
Financial Liabilities
June 30, 2022
2%...................................................................................... 	$ 	559 	$ 	215 	$ 	(3,073) 	$ 	(7,035)
1 ........................................................................................ 	280 	107 	(1,583) 	(3,824)
(1) ...................................................................................... 	(248) 	(107) 	1,666 	4,595
(2) ...................................................................................... 	(248) 	(191) 	3,380 	10,165
Note: Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of June 30, 2022, the assumed hypothetical
change in interest rates does not reflect the full 100 basis point reduction in interest income and the full 200 basis point reduction in interest income or
interest expense, as the rates are assumed not to fall below zero. As of June 30, 2022, some of our investments had interest rates below 2% so the assumed
hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.
ITEM 4. 	CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
24

-- 26 of 29 --

reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of June 30, 2022. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
June 30, 2022.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2022 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item
1A, “Risk Factors” of our 2021 10-K, which could materially affect our business, financial condition or future results. The risks
described in our 2021 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that
we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2021 10-K.
ITEM 2. 	UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Second Quarter 2022
For the Month Ended Total Number of
Shares Purchased Average Price Paid
Per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares That May Yet Be
Purchased Under The
Plans or Programs
(in millions) 	(in millions) 	(in millions)
April 30, 2022.......................................... 	1 	$ 	528.52 	1 	39
May 31, 2022........................................... 	2 	492.97 	2 	37
June 30, 2022........................................... 	2 	480.23 	2 	35
Total ..................................................... 	5 	$ 	499.30 	5
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2018, the
Board of Directors renewed our share repurchase program with an authorization to repurchase up to 100 million shares of our common stock in open market
purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.
25

-- 27 of 29 --

ITEM 6. 	EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 	Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company’s
Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 	Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated by reference to
Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on February 26, 2021)
4.1 	Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York
(incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3/A, SEC File Number 333-66013,
filed on January 11, 1999)
4.2 	Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between UnitedHealth Group
Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2001)
4.3 	Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture,
dated as of November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York
and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2007)
4.4 	Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association
(incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3, SEC File Number 333-149031,
filed on February 4, 2008)
31.1 	Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 	Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS 	XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are
embedded within the Inline XBRL document.
101.SCH 	Inline XBRL Taxonomy Extension Schema Document.
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF 	Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
* 	Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term
debt are not filed. The Company will furnish copies thereof to the SEC upon request.
26

-- 28 of 29 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/S / A NDREW P. W ITTY
Andrew P. Witty
Chief Executive Officer
(principal executive officer)
Dated: 	August 3, 2022
/S / JOHN F. REX
John F. Rex
Executive Vice President and
Chief Financial Officer
(principal financial officer)
Dated: 	August 3, 2022
/ S / T HOMAS E. ROOS
Thomas E. Roos
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: 	August 3, 2022
27

-- 29 of 29 --